Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1

Status

Completed 76Terminated 15Unknown 13Recruiting 8Withdrawn 2Suspended 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 57Breast Neoplasms 52Leukemia, Myeloid, Acute 40Carcinoma, Non-Small-Cell Lung 40Lymphoma 35Pancreatic Neoplasms 30Leukemia, Lymphocytic, Chronic, B-Cell 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 27Ovarian Neoplasms 25Multiple Myeloma 25Lymphoma, Non-Hodgkin 25Recurrence 24Lung Neoplasms 23Melanoma 22Lymphoma, Large B-Cell, Diffuse 21Prostatic Neoplasms 20Glioblastoma 20Brain Neoplasms 19Colorectal Neoplasms 18Lymphoma, Follicular 17Squamous Cell Carcinoma of Head and Neck 16Sarcoma 16Lymphoma, B-Cell 15Lymphoma, Mantle-Cell 14Myelodysplastic Syndromes 13Urinary Bladder Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Glioma 12

Interventions

nabiximols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Advanced Cancer × Clear all
NCT05262842 2022-09-21

JS001+IMP4297 in Patients With Advanced Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Withdrawn

Advanced Cancer

NCT02432612 2016-03-02

A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer

GWPharm

Phase 1 Withdrawn

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡